Big Board

Keyword
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Connective tissue disease-related ILD leads to significant workplace productivity loss
2 Unclassified Interstitial Lung Disease Leads to Poor Outcomes
3 Multidisciplinary Discussion Benefits Diagnosis, Management of ILD, Study Finds
4 Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.
5 DMARDs for Patients With Rheumatoid Arthritis-Associated ILD
6 Canadian Research Partnership Will Focus on Progressive Fibrosing ILDs
7 Assessing Rates and Risk Factors for Interstitial Lung Disease in Patients With Rheumatoid Arthritis
8 Rituximab Plus CellCept Durably Improves Lung Function in Refractory SSc-ILD, Study Suggests
9 Tumor Markers in Blood May Help Diagnose Lung Disease in Sjögren's
10 IPAF Shows Demographic and Imaging Similarities with CTD-ILD
11 Global Ofev (Nintedanib) Drug Insight and Market 2020-2030: Overview, Regulatory Milestones, Market Competitors, Emerging Therapies
12 Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease
13 Slow Lung Decline Typical in Systemic Sclerosis
14 What Happens to Patients in the First Year After ILD Diagnosis?
15 Adverse Event Profile of Nintedanib in SSc-ILD Consistent With its Safety, Tolerability Profile in Idiopathic Pulmonary Fibrosis
16 Patient Management of Chronic Fibrosing Interstitial Lung Disease With Progressive Phenotype
17 FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases
18 Submit plan in 1 week to wrap up delayed projects, ILD told
19 AST/ALT ratio as a predictor of mortality and exacerbations of PM/DM-ILD in 1 year-A retrospective cohort study with 522 cases
20 Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic
21 Does ILD Vary by Season for Hospitalization, Mortality Rates?
22 Diagnosis: Chronic Fibrosing ILD With Progressive Phenotype
23 Distinguishing Interstitial Lung Disease From COVID-19 Infection in Patients Treated With EGFR-TKIs
24 ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
25 Year in review: New treatment options, updates in ILD, IPF
26 Diagnosing Interstitial Lung Disease Using eNose Technology
27 ILD news you may have missed
28 How Does iliad S.A. (EPA:ILD) Fare As A Dividend Stock?
29 South Sudan commemorates International Literacy Day (ILD)
30 Survival After Acute Flares of Interstitial Lung Disease Varies by Fibrosis Type, Study Says
31 Journey to Diagnosis of Progressive Phenotype ILD
32 Progressive Phenotype ILD: Effect on Personal Life
33 Knowledge About Effective Therapies for Interstitial Lung Disease Lacking, Review Says
34 Methotrexate does not increase risk for rheumatoid arthritis-associated ILD
35 Nintedanib Receives Additional Indication for Chronic Fibrosing Interstitial Lung Disease
36 Systemic sclerosis-associated interstitial lung disease
37 Pulmonary Hypertension With ILD: Diagnostic and Treatment Challenges
38 FDA Approves New Treatment for Chronic Fibrosing ILD
39 Here’s Why iliad (EPA:ILD) Is Weighed Down By Its Debt Load
40 Researchers Find HRCT Risk Prediction Model Helpful in Predicting RA-ILD Prognosis
41 Gambia: On ILD 2020
42 Exclusive: French state to raise 2.8 billion euros from 5G spectrum sale
43 Progressive Phenotype ILD: Insurance Coverage | AJMC
44 Nintedanib analyses support benefit in chronic fibrosing ILDs with progressive phenotype
45 Pulmonary Function Tests Not a Good Substitute in ILD Screening
46 Precautions of Progressive Phenotype ILD During COVID-19
47 Hypersensitivity Pneumonitis Diagnosis in ILD: Questionnaires vs Serum IgG Testing
48 Interstitial lung disease exacerbates rheumatoid arthritis activity, related conditions
49 Effects of AE-ILD in Patients With Idiopathic Inflammatory Myopathy
50 Inhaled nitric oxide at higher dose shows benefit in pulmonary hypertension, fibrotic ILD
51 No Link Between Methotrexate, Interstitial Lung Disease in RA
52 New Partnership in Alberta Supports Healthcare Solutions for Interstitial Lung Diseases
53 PFF Stresses Differences Between COVID-19 and ILD Fibrosis Patterns
54 Opioids Infrequently Prescribed for Severe Breathlessness in COPD and ILD
55 Homocitrullination May Be Linked to Interstitial Lung Disease in Rheumatoid Arthritis
56 Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Forecasts to 2028: 7MM Coverage, Epidemiology Segmentation, Drugs Update and Competitor Insights
57 CHEST Releases Guideline on Transbronchial Cryobiopsy for Diagnosing ILD
58 Higher omega-3 DHA levels linked to less lung inflammation, lower ILD risk
59 Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung disease
60 Role of Lung Ultrasound in the Assessment of Interstitial Lung Disease in Systemic Sclerosis
61 ILD affects systemic sclerosis outcomes
62 Researchers Describe Concomitant Interstitial Lung Disease With Psoriasis
63 Late-Breaking Data for Daiichi Sankyo's HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be Presented at 2020 ESMO Annual Meeting
64 Have a Condition That Can Affect Breathing? What You Need to Know About COVID-19.
65 Overview and Management of Drug-Induced Interstitial Lung Disease With Novel Treatments in HER2+ Breast Cancer, Lung Cancers, and Gastrointestinal Cancers
66 Onset of Pneumothorax Carries Poor Prognosis for Patients With CTD-ILD
67 Agreement high between cryobiopsy, surgical biopsy for ILD diagnosis
68 BMI, Changes in Weight Linked to Mortality in Fibrotic Interstitial Lung Disease
69 New Analyses of Ofev® data in patients with chronic fibrosing ILDs available during American Thoracic Society Congress
70 In Certain ILD Patients, Ofev Slows Lung Function Decline, Trial Finds
71 Genetic variant in Japanese population increases risk of interstitial lung disease among RA patients
72 Nintedanib approval provides 'exciting news' for other CTD-associated ILD
73 Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
74 CHMP Favors EU Approval of Ofev for Progressive Fibrosing ILDs
75 New COVID-10 guidelines for CKD and interstitial lung disease
76 European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) | Small Molecules | News Channels
77 Expert Perspectives on the Identification and Management of Drug-Induced Interstitial Lung Disease
78 Understanding Molecular Mechanisms of Air Pollution’s Impact on Interstitial Lung Disease is Critical to Minimizing its Effects
79 Systemic Sclerosis
80 Methotrexate Not Associated with Lung Disease in RA
81 FDA grants breakthrough therapy designation to Esbriet for unclassifiable ILD
82 Perceptions, Practices in RA-ILD Differ Between Rheumatologists and Pulmonologists
83 The learning frame and interdisciplinary thinking
84 Interstitial Lung Disease (ILD)
85 Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) 2020-2028
86 FDA 'Breakthrough' status for Roche's Esbriet in unclassifiable ILD
87 Ambulatory Oxygen Therapy in Interstitial Lung Disease: Pilot Study Results
88 Inhaled Nitric Oxide at Higher Dose Improves Activity in PH Associated With ILD
89 ILD Common in Chinese Patients With Sjögren's, Worsens Quality of Life, Study Reports
90 Severe Fatigue Very Common in Pulmonary Sarcoidosis Patients...
91 INBUILD: Nintedanib slows progression of fibrosing ILD
92 1st Participant Enrolled in Phase 3 Trial Testing Ofev in Children...
93 Ofev OK'd for Progressive Fibrosing Interstitial Lung Diseases in Europe
94 Panel Develops SSc-ILD Diagnosis, Management Guidelines
95 Pirfenidone Gets Breakthrough Therapy Status for Unclassifiable Interstitial Lung Disease
96 Methotrexate is not an additional risk factor for interstitial lung disease in RA patients
97 Interstitial Lung Abnormalities, Disease More Likely in People With HIV
98 United Therapeutics Announces US FDA Filing Acceptance Of Supplemental New Drug Application For Tyvaso® For Pulmonary Hypertension Associated With Interstitial Lung Disease
99 Drug-Related Interstitial Lung Disease Can Occur at Any Time in a Treatment Course
100 New analyses of Ofev data in patients with chronic fibrosing ILD